Prognostic value of the Stanniocalcin-2/PAPP-A/IGFBP-4 axis in ST-segment elevation myocardial infarction

• DOI: 10.1186/s12933-018-0710-3
• Publication Date: 2018-04-30T05:14:17Z
• Authors: Germán Cediel; Ferran Rueda; Claus Oxvig; Teresa Oliveras; Carlos Labata; Oriol de Diego; Marc Ferrer; M. Cruz Aranda-Ne...; Judith Serra-Gregori; Julio Núñez; Cosme García; Antoni Bayes-Genis
• Keywords: Clinical endpoint; Killip class; Angiology

The aim of the present study was to evaluate prognostic value Stanniocalcin-2/PAPP-A/IGFBP-4 axis in patients with ST-segment elevation myocardial infarction (STEMI). Observational cohort performed 1085 consecutive STEMI treated early reperfusion between February 2011 and August 2014. Stanniocalcin-2, PAPP-A, IGFBP-4 were measured using state-of-the art immunoassays. primary outcome composite endpoint all-cause mortality readmission due heart failure (HF). Median follow-up 3.3 years (IQR 1.0–3.7), during which 176 (16.2%) presented a endpoint. Multivariable cox regression analysis revealed that Stanniocalcin-2 (HR 2.06; 95% CI 1.13–3.75; p = 0.018), 1.73; 1.14–2.64; 0.010), Killip–Kimball class III–IV 1.40; 1.13–1.74; 0.002), NT-ProBNP 1.21; 1.07–1.37; age 1.06; 1.04–1.08; < 0.001) left ventricular ejection fraction 0.97; 0.95–0.98; independent predictors A model containing on top clinical variables significantly improved C-index discrimination (p 0.036). also identified as predictor 2.23; 1.16–4.29; 0.017) HF 3.42; 1.22–9.60; 0.020). In patients, emerged death HF. exhibits significant role risk stratification.